No­var­tis' ip­ta­co­pan meets PhI­II test in fight against rare blood dis­ease

No­var­tis de­clared a Phase III suc­cess for its drug ip­ta­co­pan for the treat­ment of parox­ys­mal noc­tur­nal he­mo­glo­bin­uria, a rare dis­or­der in which flawed red blood …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER